News - Allergan, Mergers & Acquisitions

Filter

Popular Filters

Valeant goes hostile in $53 billion bid for Allergan

Valeant goes hostile in $53 billion bid for Allergan

18-06-2014

Canada’s Valeant Pharmaceuticals International has today commenced an exchange offer for the common…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Pershing Square files law suit over Allergan’s rights plan

Pershing Square files law suit over Allergan’s rights plan

15-06-2014

William Ackman's Pershing Square Capital Management has filed a law suit in the Delaware Court of Chancery…

AllerganLegalMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Allergan board again rejects revised unsolicited takeover bid from Valeant

Allergan board again rejects revised unsolicited takeover bid from Valeant

10-06-2014

US Botox-maker Allergan says that its board of directors, after consulting with its independent financial…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Allergan warns shareholders to take no action ahead of Valeant calling ‘special meeting’

Allergan warns shareholders to take no action ahead of Valeant calling ‘special meeting’

03-06-2014

Takeover target USA-based Allergan has responded to action taken by Canadian drugmaker Valeant Pharmaceuticals…

AllerganBusiness FinanceMergers & AcquisitionsPharmaceuticalUSAValeant PharmaceuticalsValeant Pharmaceuticals International

Valeant goes even further, upping recently sweetened offer for Allergan

Valeant goes even further, upping recently sweetened offer for Allergan

02-06-2014

Even before it received an official response from its takeover target US Botox-maker Allergan, acquisitive…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Valeant ups offer for Allergan as target publishes attack on its business model

Valeant ups offer for Allergan as target publishes attack on its business model

28-05-2014

Canadian drugmaker Valeant Pharmaceuticals International has today upped its offer for USA-based Allergan…

AllerganBusiness FinanceBusiness FinanceCanadaMergers & AcquisitionsPharmaceuticalUSAValeant PharmaceuticalsValeant Pharmaceuticals International

Allergan board totally rejects Valeant’s $46 billion bid

Allergan board totally rejects Valeant’s $46 billion bid

13-05-2014

USA-based Allergan said yesterday that its board of directors has unanimously rejected the $46 billion…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Takeover target Allergen reports strong 1st-qtr sales growth

07-05-2014

US drugmaker Allergan reported a strong set of first-quarter 2014 financial results, with global sales…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Allergan adopts stockholder rights plan

23-04-2014

USA-based Allergan, the subject of a hostile takeover bid from Canada’s Valeant Pharmaceuticals reported…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Valeant joins with hedge fund in $45.6 billion unsolicited bid for Allergan

22-04-2014

Canada’s Valeant Pharmaceuticals International, never shy to go for hostile takeover moves, says it…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Allergan reports 3rd-qtr sales rise of 12.9%, plans disposal

29-10-2013

US drugmaker Allergan has posted a strong set of financial results for the third quarter of 2013, with…

AllerganFinancialMergers & Acquisitions

Zoetis IPO caps strong month for life sciences financings, says Burrill & Co

04-02-2013

Life sciences financing activity got a strong start in the New Year as companies raised $10.3 billion…

AllerganBiotechnologyFinancialMAP PharmaceuticalsMergers & AcquisitionsPfizerPharmaceuticalZoetis

Allergan to acquire MAP Pharmaceuticals in $958 million deal

24-01-2013

US drugmaker Allergan (NYSE: AGN) has entered into a definitive merger agreement to acquire 100% of the…

AllerganLevadexMAP PharmaceuticalsMergers & AcquisitionsNeurologicalPharmaceutical

Allergan to acquire SkinMedica business for $350 million

18-11-2012

US drug firm Allergan (NYSE: AGN), best known as the maker Botox (onabotulinumtoxinA) anti-wrinkle injections,…

AllerganDermatologicalsMergers & AcquisitionsPharmaceuticalSkinMedica

Allergan 4th-qtr revenues up 6%; earnings exceed expectations

31-10-2012

US health care firm Allergan (NYSE: AGN) revealed yesterday that revenues for its fiscal fourth-quarter…

AllerganFinancialMergers & AcquisitionsPharmaceutical

Back to top